| 產(chǎn)品描述： | P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease |
| 體內(nèi)研究： |
P7C3 (20 mg/kg/d; i.p.; twice daily; for 21 days ) inhibits microglial activation and microglia-mediated dopaminergic (DA) neuronal loss in vivo |
| 參考文獻： |
1. Pieper AA et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010 Jul 9;142(1):39-51. 2. Pieper AA et al. P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev. 2014 Oct 7;43(19):6716-26. 3. Chao Gu , et al. P7C3 Inhibits LPS-Induced Microglial Activation to Protect Dopaminergic Neurons Against Inflammatory Factor-Induced Cell Death in vitro and in vivo. Front Cell Neurosci. 2018; 12: 400. 4. Blaya MO, Wasserman JM, Pieper AA, Sick TJ, Bramlett HM, Dietrich WD. Neurotherapeutic capacity of P7C3 agents for the treatment of Traumatic Brain Injury. Neuropharmacology. 2019;145(Pt B):268-282. |
| 溶解性： |
DMSO : ≥ 33 mg/mL (69.59 mM) |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.109 ml |
10.544 ml |
21.088 ml |
| 5 mM |
0.422 ml |
2.109 ml |
4.218 ml |
| 10 mM |
0.211 ml |
1.054 ml |
2.109 ml |
| 50 mM |
0.042 ml |
0.211 ml |
0.422 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京